4//SEC Filing
Sabba Stephen L 4
Accession 0001104659-22-070992
CIK 0000886163other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 3:56 PM ET
Size
9.3 KB
Accession
0001104659-22-070992
Insider Transaction Report
Form 4
Sabba Stephen L
Director
Transactions
- Award
Common Stock
2022-06-10+1,004→ 26,065 total - Award
Non-Qualified Stock Option (right to buy)
2022-06-10−4,340→ 4,340 totalExercise: $79.29Exp: 2032-06-10→ Common Stock (4,340 underlying)
Holdings
- 3,269
Non-Qualified Stock Option (right to buy)
Exercise: $115.39Exp: 2031-06-04→ Common Stock (3,269 underlying)
Footnotes (3)
- [F1]These securities, as represented in Column 5, include a grant of 1,004 restricted share units approved by the Board of Directors of the Company at the 2022 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
- [F2]These securities, as represented in Column 5, were acquired by a grant of 4,340 shares approved by the Board of Directors of the Company at the 2022 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.
- [F3]These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 8, 2021.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001442372
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 3:56 PM ET
- Size
- 9.3 KB